Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02044120 · ClinicalTrials.gov registry record · Phase 1
ESP1/SARC025 Global Collaboration: A Phase I Study of a Combination of the PARP Inhibitor, Niraparib and Temozolomide and/or Irinotecan Patients With Previously Treated, Incurable Ewing Sarcoma
A Phase 1 study, sponsored by Sarcoma Alliance for Research through Collaboration.
- Completed
- Registry status
- Phase 1
- Development phase
- 34
- Enrollment target
NCT02044120 is a Phase 1 study that has completed, run by Sarcoma Alliance for Research through Collaboration. The registered enrollment target is 34 participants.
The verdict
NCT02044120, a Phase 1 study, has completed, sponsored by Sarcoma Alliance for Research through Collaboration.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 34 participants
- Enrollment target
Study Summary
The purpose of this study is to define the dose-limiting toxicities and maximum tolerated dose of the poly ADP-ribose polymerase inhibitor niraparib and escalating doses of temozolomide and/or irinotecan in patients with pre-treated incurable Ewing sarcoma.
Interventions
- DRUG Temozolomide
- DRUG Irinotecan
- DRUG niraparib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34 participants |
| Start Date | 2014-05 |
| Est. Completion | 2021-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02044120
The ClinicalTrials.gov registry entry for NCT02044120 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 34 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sarcoma Alliance for Research through Collaboration, which has 20 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Temozolomide is the first listed.
NCT02044120 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02044120 about?
NCT02044120 is a clinical study titled "ESP1/SARC025 Global Collaboration: A Phase I Study of a Combination of the PARP Inhibitor, Niraparib and Temozolomide and/or Irinotecan Patients With Previously Treated, Incurable Ewing Sarcoma". The purpose of this study is to define the dose-limiting toxicities and maximum tolerated dose of the poly ADP-ribose polymerase inhibitor niraparib and escalating doses of temozolomide and/or irinotecan in patients with pre-treated incurable Ewing sarcoma.
What is the current status of trial NCT02044120?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 34 participants. The study started on 2014-05. Estimated completion is 2021-01.
What interventions are being tested in trial NCT02044120?
The interventions under investigation include: Temozolomide (DRUG), Irinotecan (DRUG), niraparib (DRUG).
Who is sponsoring clinical trial NCT02044120?
This trial is sponsored by Sarcoma Alliance for Research through Collaboration, which has 20 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.